Dexcom | DXCM - Gewinn Vor Steuern

Aktienkurs
61.53
Täglich Wechseln
1.98 3.32%
Monatlich
-1.11%
Jährlich
-24.61%
Q2 Prognose
60.25




Gewinn Vor Steuern Veränderung Datum
Abbott USD 2.39B 27M 2026-03
Align Technology USD 148.89M 27.71M 2026-03
AtriCure USD 2.36M 2.45M 2025-12
Avanos Medical USD -1.2M 74.7M 2025-09
Baxter International USD -756M 877M 2025-12
Becton, Dickinson and Co. USD 393M 117M 2025-12
Boston Scientific USD 700M 238M 2025-12
Cooper Companies USD 116.8M 137.4M 2025-09
Dexcom USD 340.7M 40.7M 2025-12
Edwards Lifesciences USD 348.4M 51.8M 2025-09
Globus Medical USD 143.99M 44.18M 2025-09
Inogen USD -6.06M 467K 2024-09
Insulet USD 140.2M 17.4M 2025-12
Integra LifeSciences USD -6.82M 524.13M 2025-09
J&J USD 7.82B 2.86B 2026-03
Masimo USD 74.9M 19.5M 2025-09
Medtronic USD 2.1B 224M 2025-09
Merit Medical Systems USD 51.06M 22.12M 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Solventum Corp USD 511M 149M 2025-09
Stryker USD 1.7B 676M 2025-12
Tandem Diabetes Care USD -25.14M 32.58M 2025-09
Teleflex USD -438.58M 573.82M 2025-09
West Pharmaceutical Services USD 161.5M 8.6M 2025-12
Zimmer Biomet Holdings USD 98M 320.7M 2025-12